{Reference Type}: Journal Article
{Title}: Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.
{Author}: Sree RA;Gupta A;Gupta N;Veturi S;Reddy LSK;Begum M;Shravani E;Challa HR;Reddy SS;Singamsetty A;Arumilli M;Reddy PN;Tirlangi PK;
{Journal}: Infection
{Volume}: 52
{Issue}: 2
{Year}: 2024 Apr 11
{Factor}: 7.455
{DOI}: 10.1007/s15010-023-02094-9
{Abstract}: <B>BACKGROUND: </B>Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections commonly cause hospital-acquired infections. The study aimed to compare the outcomes of CRKP infections between patients receiving ceftazidime avibactam +/- aztreonam and polymyxins in a hospital setting with a high prevalence of New Delhi Metallo Beta Lactamase production.<BR><B>METHODS: </B>We conducted a retrospective cohort study from January 2020 to September 2022 in critically ill adult patients admitted to a non-COVID-19 medical intensive care unit with CRKP infection. The patients were followed up for a total of 30 days or death, whichever was later.<BR><B>RESULTS: </B>Of a total of 106 patients included in the study, 65 patients received polymyxins and 41 patients received ceftazidime-avibactam +/- aztreonam. Higher 30-day mortality was noted in the polymyxin group (56.9% vs. 29.2%, P = 0.005). The mean time to event (mortality) in ceftazidime-avibactam +/- aztreonam was 23.9 + 1.5 days which was significantly higher compared to polymyxins (17.9 + 1.2 days, p = 0.006). On Cox regression analysis, after adjusting for the covariates, the hazard ratio for time to event with the use of polymyxin was 2.02 (95% CI: 1.03-3.9).<BR><B>CONCLUSIONS: </B>Ceftazidime-avibactam + aztreonam is possibly associated with better clinical outcomes in patients infected with CRKP.